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Abstract
There is a growing international literature investigating the relationship between attention-deficit/hyperactivity disorder 
(ADHD) and younger relative age within the school year, but results have been mixed. There are no published systematic 
reviews on this topic. This study aimed to systematically review the published studies on the relative age effect in ADHD. 
Systematic database searches of: Medline, Embase, PsycINFO, Web of Science, ERIC, Psychology and Behavioral Sciences 
Collection and The Cochrane Library were conducted. Studies were selected which investigated the relative age effect in 
ADHD in children and adolescents. Twenty papers were included in the review. Sixteen (of 20) papers reported a signifi-
cantly higher proportion of relatively younger children being diagnosed with ADHD and/or receiving medication for this. 
Meta-analyses involving 17 of these 20 papers revealed a modest relative age effect in countries with higher prescribing 
rates, risk ratio = 1.27 (95% CI 1.19–1.35) for receipt of medication. The relative age effect is well demonstrated in countries 
with known higher prescribing rates. Amongst other countries, there is also increasing evidence for the relative age effect, 
however, there is high heterogeneity amongst studies. Further research is needed to understand the possible reasons under-
pinning the relative age effect and to inform attempts to reduce it.
Keywords ADHD · Relative age
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a com-
mon childhood neuro-developmental disorder, character-
ised by three core symptoms: inattention, hyperactivity 
and impulsiveness causing an impairment in functioning 
[1]. Although epidemiological studies suggest that globally 
ADHD affects around 5% of school-age children, diagnosis 
and prescription rates are heterogeneous between countries 
[2–7] and estimated prescribing rates vary, for example, 
from 0.9% in Denmark to 4.6–4.7% in Canada and Iceland 
[8].
The receipt of a clinical diagnosis of ADHD depends on 
evidence of symptoms affecting functioning in more than 
one setting, for example, both at school and at home. The 
diagnostic process, therefore, usually involves the collection 
of information from those who encounter the child in dif-
ferent contexts, for example, the child’s parents and school 
teachers, as well as the observations and interpretation of 
the health care professionals conducting the assessment [1].
There is an overwhelming literature documenting neu-
robiological, clinical and pharmacological evidence for the 
validity of ADHD as a diagnosis [9]. Despite the operation-
alization of the diagnostic process, since diagnosis involves 
clinical judgment, without an objective test, there remain 
a number of areas of debate within the literature [10, 11]. 
This systematic review focuses on one debate, whether rela-
tive age within the academic year affects the likelihood of a 
child being diagnosed with and/or receiving medication for 
ADHD. In many countries, there is a set age at which a child 
starts their first year of school, with a chronological date 
cut-off, e.g. 1st of September. This means that one child, 
born early in September may be 5 years old when the aca-
demic year starts, however, a child born at the end of August 
will only recently have turned 4 years of age. It would be 
expected that the older child will be more developmentally 
 * Josephine Holland 
 josephine.holland@nottingham.ac.uk
1 Division of Psychiatry and Applied Psychology, 
School of Medicine, CANDAL (Centre for ADHD 
and Neurodevelopmental Disorders across the Lifespan), 
Institute of Mental Health, University of Nottingham, 
Nottingham, UK
 European Child & Adolescent Psychiatry
1 3
mature than the younger child, however, the academic and 
developmental expectations for the two children are likely 
to be similar, especially at school. The relative age effect is 
well evidenced within sport [12] and academic achievement 
[13]. It has also been studied with regard to child mental 
health problems [14]. There is no single accepted definition 
of younger relative age within the literature. Here we refer to 
children born at least in the younger half of the school year, 
however, others have defined this as the youngest one, two, 
three or 4 months of the year.
In relation to ADHD, the relative age effect has usually 
been demonstrated in countries with high prescribing rates 
for ADHD [15, 16], whereas findings from countries with 
lower prescribing rates have been mixed [2, 17, 18]. This 
area has important implications for diagnostic and prescrib-
ing practice as well as school entry policy. It has been argued 
that the relative age effect may represent the more immature 
behaviour of younger children being diagnosed and treated 
as ADHD and, therefore, more relaxed school entry policies 
may be able to offset this [15, 17]. This systematic review 
aims to investigate the strength of evidence for a relative 
age effect, distinguishing countries known to have higher 
and lower prescribing rates [19, 20]. It addresses three key 
questions—Is there an association between younger relative 
age, defined as being in the second half of the academic year, 
and: (1) the presence of high levels of ADHD symptoms, (2) 
receiving a clinical diagnosis of ADHD and (3) receiving 
medication for ADHD?
Methods
A literature search was conducted with the assistance of 
an information specialist. This covered articles published 
from the 1st of January 2000 to the search date of the 7th 
September 2017. Databases searched included: MEDLINE, 
EMBASE, PsycINFO, Web of Science, ERIC, Psychology 
and Behavioural Sciences Collection and The Cochrane 
Library. Search keywords comprised: (1) Various terms for 
ADHD including: Attention Deficit Disorder with Hyperac-
tivity, ADHD, ADDH, ADHS, hyperkinesis, hyperactive* 
and inattention* and (2) Relative age, relative maturity, 
relative immaturity, young for grade, young for year, old 
for grade or old for year. Additional studies were identi-
fied through checking reference lists of obtained articles. 
A further update search using the same search terms and 
databases was conducted on the 23rd of November 2017.
Abstracts were screened independently by JH and KS 
with 100% agreement, and then full text assessments were 
conducted by JH. All articles were available to download 
from online sources. Studies not published in English were 
translated by colleagues (n = 2) and assessed by JH.
Inclusion criteria
Research articles were included which reported data from: 
a dimensional measure of ADHD symptoms, diagnoses 
or prescription provision amongst children or adolescents 
up to 18 years of age, where chronological age, includ-
ing month (either reported as grouped months or actual 
month) of birth of participants, was recorded.
Exclusion criteria
Papers were excluded for the following reasons: were case 
reports or conference abstracts; only data for individuals 
aged over 18 were used; no chronological age by month of 
birth data was recorded, and/or they focused on disorders 
or behaviour problems but did not specifically report on 
ADHD. Intervention studies were excluded unless they 
contained relative age comparison data.
Analysis
Each study was assessed for bias using a modified version 
of the Newcastle–Ottawa assessment scale (NOS; [21]). 
The NOS scores a study based on its selection methods, 
comparability and outcome measures. Since the studies 
included in this review did not include an exposure, ques-
tions which related to this were excluded. A study could, 
therefore, score a minimum of 0 (low quality, high risk of 
bias) to a maximum of 6 (high quality, low risk of bias). 
Data were extracted and inputted into Review Manager 
version 5.3 for analysis. This review aimed to describe 
the literature and, where possible, conduct a quantitative 
analysis of the data via meta-analysis.
For the studies which met the inclusion criteria, data 
were extracted for the total number of children within 
each comparison group and the number of children who 
received a diagnosis of ADHD or ADHD medications. If 
a study met inclusion criteria but did not report the data 
in a format which could be included in the quantitative 
analysis, the authors were contacted to request the required 
figures.
Studies were divided based on country of origin, sepa-
rating those from countries known to have higher rates of 
prescribing for ADHD (e.g. USA, Canada, Iceland and 
Israel), and those with lower rates (e.g. other European 
countries and Australia; [8]). For Germany, studies have 
reported prescribing prevalence rates ranging from 2.2% 
[22] to above 4% [20] and so, for the purposes of our anal-
yses, will be treated as a high prescribing country. Where 
a study presented a number of comparisons, for example, 
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children from the first month of the academic year and the 
last month as well as children from the first 4 months of 
the year compared to the last 4 months of the year, both 
comparisons were inputted into the analysis.
Due to high heterogeneity between studies, a random 
effects model using the Mantel–Haenszel method was used. 
Risk ratios (RR) with 95% confidence intervals were pre-
sented as the effect measure as this is the most commonly 
presented measure in studies.
Results
A total of 123 references were retrieved through initial data-
base searches and four through reference checking. A further 
two references were identified through the update search. 
After duplicates were removed, 63 abstracts were screened. 
Thirty records were excluded on the basis of: not relating to 
ADHD (9), response letters/reviews (4), case reports (5), no 
birth month information (8), adult data only (2) and tests of 
intervention (2).
The remaining 33 full-text articles were reviewed. A 
further 13 of these were excluded due to: no birth month 
information (1), ADHD not being separate from other child 
mental health disorders (1) and conference abstracts (11).
Twenty studies were assessed for the review and data 
extraction, the characteristics of these studies are shown in 
Table 1. Six of these could not be included in the quantitative 
synthesis initially due to: information not being presented on 
the total number of children, with and without a diagnosis/
medication receipt [8, 19, 22, 24, 25] or comparisons only 
being made between the starting school age not age within 
the school year [26]. However, following communications 
with the authors, data were provided for three studies [8, 20, 
25] and were therefore included. The PRISMA flowchart for 
study selection is presented in Fig. 1.
For the three studies which included measures of ADHD 
symptoms, two showed evidence of a relative age effect. 
This was from symptom reports from teachers [27, 35] with 
weaker evidence of an effect from parents’ reports [35]. In 
contrast, the third did not show evidence of a relative age 
effect in parent-reported levels of symptoms [25]. A meta-
analysis was not possible since the results were not directly 
comparable due to the use of different types of rating scales, 
e.g. Strengths and Difficulties Questionnaire, social rating 
scales and Autism–Tics, ADHD and other Comorbidities 
inventory.
For studies investigating the proportion of children 
receiving a diagnosis and/or medication, data were extracted 
and meta-analyses were conducted, separating studies into 
subgroups based on the outcomes studied (diagnosis or pre-
scription) and whether the country was known to have higher 
or lower rates of ADHD prescribing. However, heterogeneity 
estimates were too high, for an overall analysis (diagnosis 
I2 = 97%, prescriptions I2 = 95%) to be presented.
A meta-analysis of the studies investigating the propor-
tion of children receiving medication in higher prescribing 
countries showed a significant relative age effect with those 
younger in the academic year being more likely to receive 
medication for ADHD (I2 = 74%, RR 1.27 (1.19–1.35)), 
as shown in Fig. 2. However, the meta-analysis of studies 
reporting the proportion who received a diagnosis showed 
high heterogeneity  (I2 = 91%) and therefore is not presented 
here, Fig. 3 shows the risk ratio from each study.
For the other countries, heterogeneity estimates were too 
high for reporting of the meta-analysis for either diagnosis 
or medication, I2 = 98% and I2 = 97%, respectively, as shown 
in Figs. 4 and 5.
As shown within the risk-ratio plots, almost all studies 
have shown, to some extent, higher proportions of ADHD 
diagnosis and prescriptions amongst the youngest in the 
academic year. The studies which did not show a significant 
relative age effect were from Denmark (RR 0.91, 95% CI 
(0.86–0.96); [17] and RR 1.02, 95% CI (0.97–1.07); [18]), 
and one from Germany (RR 1.55, 95% CI (0.51–2.95); 
[35])). However, there is variation in the magnitude of the 
risk ratio estimates between different studies, e.g. one find-
ing that children born in the youngest month of the academic 
year were over 1.6 times more likely to be diagnosed with 
ADHD (RR 1.61, 95% CI (1.46–1.78)) and to receive medi-
cation (RR 1.75, 95% CI (1.55–1.98)), compared with the 
children born in the month after the cut-off [29]. In com-
parison, a study from Israel showed an increased risk ratio 
of around 1.2 for the youngest third of the school year, com-
pared with the oldest third (RR 1.17, 95% CI (1.12–1.23) 
[23].
Discussion
This review has found that the majority of studies show evi-
dence of a relative age effect influencing both the diagnosis 
of and receipt of medication for ADHD. This was demon-
strated most clearly within studies from higher prescribing 
countries, with a modest pooled risk estimate of 1.27 for 
medication amongst the youngest in the school year com-
pared with their older peers in the same school year. Data 
from the other countries were more mixed, with high levels 
of heterogeneity.
Differences between study results might reflect methodo-
logical differences. As shown in Table 1, studies differed 
by sample size, years studied, ages studied and methods of 
reporting and recording ADHD diagnosis and medication. 
However, a number of other factors may contribute to the 
differences found across studies.
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Fig. 1  PRISMA flow diagram
Records idenfied through 
database searching
(n = 125  )
Addional records idenfied 
through other sources
(n = 4  )
Records aer duplicates removed
(n = 63  )
Records screened
(n =  63 )
Records excluded
(n =  30 )
• Not related to ADHD 
(9)
• No birth month 
informaon (8)
• Studies of adults (2)
• Case reports (5)
• Arcle responses (4)
• Tests of intervenons 
(2)
Full-text arcles assessed 
for eligibility
(n = 33  )
Full-text arcles excluded
(n = 13  )
• No birth month 
informaon (1)
• ADHD not separated 
from other diagnoses 
(1)
• Conference abstracts 
(11)
Studies included in 
qualitave synthesis
(n = 20  )
Studies included in 
quantave synthesis 
(meta-analysis) 
(n = 17)
Unable to include in 
quantave synthesis (n=3)
• Unable to ascertain 
group totals (2)
• Comparisons 
between age of 
starng school not
within school year (1)
Fig. 2  A Forest plot of studies comparing proportions receiving med-
ication for ADHD between the oldest and youngest within the school 
year in higher prescribing countries. *Evans 2010 appears twice in 
this Figure due to presentation of data from Medical Expenditure 
Panel Survey (line 2) and Private Insurance claims (line 4) compari-
sons separately
 European Child & Adolescent Psychiatry
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First, as noted above, there are significant variations in 
the estimated rates of ADHD diagnosis and medication 
provision between countries [8]. Schwandt and Wupper-
mann [20] plotted the relative effect sizes of the relative 
age effect against diagnosis prevalence rates. They found 
a positive correlation, with countries with higher overall 
prevalence rates showing a larger relative age effect, an 
effect which was also shown between different regions in 
Germany. This suggests the possibility of misdiagnosis 
in relation to children with young relative age. However, 
this explanation does not fit with findings from a study 
using data from Finland, a country with low diagnosis 
and prescription rates but with evidence of a relative age 
effect [19].
Fig. 3  A risk-ratio plot of studies comparing proportions receiving a diagnosis of ADHD between the oldest and youngest within the school year 
in higher prescribing countries
Fig. 4  A risk-ratio plot of studies comparing proportions receiving 
a diagnosis of ADHD between the oldest and youngest within the 
school year in other countries. *Chen 2016 appears twice in this fig-
ure due to presenting comparison of the oldest ¼ of the year com-
pared with the youngest ¼ (line 4) and the presentation of those born 
in the first month of the academic year and the last month (line 7). 
Rivas-Juesas 2015 appears twice in this figure due to data comparing 
the oldest 1/3 of the year compared with the youngest 1/3 (line 6) of 
the year and the oldest 6 months of the year compared to the youngest 
6 months (line 3)
Fig. 5  A risk-ratio plot of studies comparing proportions receiving 
medication for ADHD between the oldest and youngest within the 
school year in other countries. *Chen 2016 appears twice in this fig-
ure due to presented comparison of the oldest ¼ of the year compared 
with the youngest ¼ (line 5) and those born in the first month of the 
academic year and the last month (line 6). Pottegard 2014 appears 
twice in this figure due to presented comparisons of those born in the 
oldest 1 month and the youngest 1 month of the year (line 3) and the 
oldest 2 months compared with the youngest 2 months (line 1)
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Second, linked to the above, there are differences in diag-
nostic practice across countries, for example, which profes-
sionals are able to give a diagnosis [15, 17]. The culture of 
diagnostic practice within a country’s health system may 
have an influence on the relative age effects found.
Third, school entry regulations and policy may play a 
role. Some studies have highlighted the possibility of chil-
dren being held back an academic year as a possible factor 
influencing the magnitude of relative age estimations and 
contributing to heterogeneity [15, 17, 29]. Not only do coun-
tries differ in their age of school entry, but also in the extent 
to which these regulations are adhered to. For example, in 
Taiwan, children may possibly attend school 1 year early 
because of an arrangement between parents and teachers, 
purposefully rendering them the youngest [29]. In the US 
in the mid-1990s, around 10% of pupils delayed entry into 
kindergarten, this was more common for boys and for those 
with developmental delay [15]. In comparison, in Den-
mark, only 60% of children born in the last quarter before 
the cut-off date are enrolled in school for their assigned year 
[17]. In Israel, parents often opt or are recommended by the 
child’s kindergarten teacher to delay the commencement of 
school [23]. However, in the study from Iceland [16] just 
0.7% of children were estimated to be either a year ahead or 
behind. If immaturity being mistaken for ADHD is a cause 
of higher rates of diagnosis and medication amongst those 
youngest in the year, encouraging greater awareness of this 
amongst parents, pre-school staff and clinicians may be use-
ful in addressing the relative age effect. However, research 
is needed on the potential benefits and harms of holding 
children back a year, e.g. moving children to be the oldest 
within a year group could increase adults’ expectations of 
them [36, 37].
Fourth, teacher perceptions, in particular, may play a role. 
Elder [27] demonstrated that teachers’ ratings of ADHD 
symptoms showed a significant relative age effect, having 
a much greater magnitude than parents’ ratings. This sug-
gests that teachers are more likely to compare children with 
others in the same school year rather than by chronological 
age and thus may contribute to the possible over-diagnosis 
of ADHD in younger children. In support of this finding, 
other studies have found no relative age effect in parental 
reports of symptoms or self-reported symptoms from adults 
with ADHD [25].
Strengths and limitations
To our knowledge, this is the first systematic review of the 
association between relative age and ADHD. This review 
has identified and brought together existing research in a 
rigorous and systematic manner, enabling meta-analyses of 
the data, where possible. However, there are a number of 
potential limitations. First, since there are a number of dif-
ferent ways in which the relative age effect can be flagged 
within a study’s title and abstract there is a risk that some 
studies may have been missed. Second, some studies did not 
publish their data in a form which could be inputted to the 
meta-analysis. This meant that some large studies within 
the field could not be included in the meta-analysis [19, 24]. 
Others excluded children born in the first or last months 
of the academic year due to their likelihood of being held 
back [23, 31], this may have introduced bias within the data. 
Third, high levels of heterogeneity meant that it was not 
always possible to conduct a meta-analysis.
Clinical and research implications
These findings have significant clinical implications. Since 
there is mounting evidence of a relative age effect on ADHD 
diagnosis and medication in most countries studied, which 
may imply possible misdiagnosis of relatively immature 
children, it is possible that some relatively young children 
may be unnecessarily offered and exposed to medication, 
the long-term effects of which are still not fully understood. 
When assessing for ADHD, clinicians should also bear in 
mind that teachers may be more likely than parents to apply 
same year-group peer referencing when completing rating 
scales [27].
In terms of educational implications, these findings 
should be considered in relation to school entry regulations. 
It may be that through more flexible school entry criteria, 
relatively immature children may be allowed more time to 
develop prior to entering schooling and potentially avoid 
unnecessary diagnosis and medication.
In terms of research, further work is needed to under-
stand whether the relative age effect is due to misdiagno-
sis of younger children, for example through a longitudinal 
study showing whether these children continue to meet cri-
teria for ADHD at later stages. Although some studies have 
explored the association between certain population charac-
teristics and a relative age effect, further work is needed to 
explore the mechanisms under-pinning this effect. Family 
studies examining whether these relatively young children 
lack familiality of the disorder would also be useful. The 
literature to date has used epidemiological data. Qualita-
tive research, in particular, could be useful in improving 
our understanding about the processes contributing to the 
relative age effect.
Conclusions
This systematic review and meta-analysis has drawn together 
worldwide studies investigating the relative age effect in the 
symptoms, diagnosis and medication treatment of ADHD 
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amongst children and adolescents. It has shown that the 
relative age effect is evident in the majority of countries, 
however, there is considerable variation in its magnitude. 
Possible explanations include: overall diagnostic rates, 
national differences in diagnostic practice and school entry 
regulations and the influence of different informant sources. 
In isolation, none of these theories are able to fully explain 
the differences shown. Further research is needed to better 
understand the reasons for the relative age effect. At an indi-
vidual level it is crucial for clinicians to consider a child’s 
relative age when assessing for ADHD.
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